France: Mid-2021 for Sanofi COVID-19 Vaccine; 1 Million Domestic Cases; Ipsen Growth

face
main_img

A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales growth in 2020 despite the pandemic, diagnostics biotech Novacyt’s remarkable rise, and a new job for former Ipsen boss Marc de Garidel.

 

Sanofi aims for COVID-19 vaccine by mid-2021 (Anadolu Agency)

French pharma giant Sanofi has claimed to have stepped up its efforts to roll-out a COVID-19 vaccine by the middle of next year.

https://www.aa.com.tr/en/europe/sanofi-aims-for-covid-19-vaccine-by-mid-2021/2004960

 

Ipsen Delivers Sales Growth in the First Nine Months of 2020 Despite the Impact of COVID-19 (Business Wire)

David Loew, Chief Executive Officer of Ipsen stated: “The Group delivered a resilient performance in the third quarter, despite the continued impact of the pandemic”

https://www.businesswire.com/news/home/20201021006087/en/Ipsen-Delivers-Sales-Growth-in-the-First-Nine-Months-of-2020-Despite-the-Impact-of-COVID-19-and-Confirms-Its-2020-Full-Year-Guidance

 

French Coronavirus Cases Jump Over 1 Million (Pharmalive)

This makes France the seventh country to report more than one million coronavirus cases, after the United States with 8.4 million, India with 7.8 million, Brazil with 5.3 million and Russia with 1.5 million. Argentina and Spain have each reported just over one million.

https://www.pharmalive.com/french-coronavirus-cases-jump-over-1-million/

 

How French pharma firm Novacyt has turned £10,000 into nearly £1m supplying the world with Covid tests (This is Money)

An investor with £1,000 of shares in Novacyt at the start of the year would now have nearly £92,000. Someone with a £10,000 holding would have close to £1million.

https://www.thisismoney.co.uk/money/markets/article-8873579/MARKET-REPORT-Novacyt-turned-10-000-nearly-1m.html

 

Ex-Ipsen boss de Garidel takes the helm at AZTherapies (FierceBiotech)

“What was a bit special about AZTherapies was the fact that it was very advanced in late-stage clinical development. We will know very quickly early next year whether this is going to work or not,” de Garidel said.

https://www.fiercebiotech.com/biotech/ex-ipsen-boss-de-garidel-takes-helm-at-aztherapies

Add Your Comment


You must be logged in to post a comment.

Related Content

Latest Report